• Chemed Corporation reported past second-quarter 2026 results showing net income of US$67.7 million versus US$52.49 million a year earlier, with diluted earnings per share from continuing operations rising to US$5.13 from US$3.57, and continued progress on a long-running buyback that has retired 12.57 million shares for US$2.91 billion.
• On top of this earnings improvement and share repurchase activity, activist investor Barington Capital has escalated its campaign, calling for a strategic review, cost cuts, and board changes, arguing Chemed’s two core businesses are not realizing their full potential.
• We will now examine how Chemed’s stronger earnings and intensifying activist pressure could influence its investment narrative and future capital allocation.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Chemed Investment Narrative Recap

To own Chemed, you need to be comfortable with a story built around stable hospice demand at VITAS and cash generation from Roto Rooter, while accepting reimbursement and volume risks in both. The latest earnings beat and ongoing buybacks support that cash generation narrative, but the biggest near term swing factor now is how the board responds to Barington’s activist push. The key risk remains pressure on VITAS’s Medicare driven economics, which this news does not materially change.

The most relevant update is Chemed’s second quarter 2026 result, with net income of US$67.7 million and diluted EPS from continuing operations of US$5.13, up from US$3.57 a year ago. This earnings strength, alongside an active buyback that has retired more than 12.57 million shares for US$2.91 billion, provides a stronger backdrop as the board weighs Barington’s calls for a strategic review and cost reductions that could meaningfully affect future capital allocation priorities.

Yet investors should also be aware that if Medicare reimbursement rules shift again or admission patterns change unexpectedly, especially in Florida...

Chemed’s narrative projects $3.1 billion revenue and $397.9 million earnings by 2029. This requires 6.3% yearly revenue growth and a $122.9 million earnings increase from $275.0 million today.

Uncover how Chemed's forecasts yield a $501.50 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming Chemed could lift earnings to about US$417.5 million by 2029, which is far more upbeat than consensus and rests heavily on smoother Medicare cap exposure and admission mix improvements; the latest activist pressure and Q2 beat could either reinforce or challenge that view, so it is worth comparing these best case assumptions with more cautious scenarios.

Explore 3 other fair value estimates on Chemed - why the stock might be worth as much as 28% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Chemed research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.